Satellos Bioscience Inc.
NASDAQTotal Valuation
Satellos Bioscience Inc. carries a market capitalization of 8.75M, placing it among publicly traded companies globally. Its enterprise value stands at 168.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.75M |
| Enterprise Value | 168.20M |
Share Statistics
Satellos Bioscience Inc. currently has 20.83M shares outstanding.
| Shares Outstanding | 20.83M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 3.84 |
| P/TBV Ratio | 3.84 |
| P/FCF Ratio | -6.76 |
| P/OCF Ratio | -6.75 |
Financial Position
Satellos Bioscience Inc. maintains a current ratio of 11.22, meaning it holds 11.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.22 |
| Quick Ratio | 10.68 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -70.45 |
| Return on Assets (ROA) | -64.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 154,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Satellos Bioscience Inc.'s stock has declined approximately -4.09605% over the past 52 weeks. The 50-day moving average sits at 8.87, while the 200-day moving average is 8.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | -4.09605% |
| 50-Day Moving Average | 8.87 |
| 200-Day Moving Average | 8.49 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -35.82M, while operating income came in at -35.82M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -35.82M |
| Pretax Income | -34.46M |
| Net Income | -34.61M |
| EBITDA | -35.82M |
| EBIT | -35.82M |
| Earnings Per Share (EPS) | -1.95 |
Balance Sheet
Total book value stands at 59.91M, with working capital of 59.90M providing operational flexibility.
| Cash & Cash Equivalents | 61.84M |
| Total Debt | N/A |
| Net Debt | -7.39M |
| Equity (Book Value) | 59.91M |
| Book Value Per Share | 2.88 |
| Working Capital | 59.90M |
Cash Flow
Satellos Bioscience Inc. produced -29.00M in operating cash flow over the past twelve months. After subtracting -7,000.00 in capital expenditures, free cash flow totaled -29.01M - equivalent to -1.64 per share.
| Operating Cash Flow | -29.00M |
| Capital Expenditures | -7,000.00 |
| Free Cash Flow | -29.01M |
| FCF Per Share | -1.64 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -22.95 |
| FCF Yield | -14.80 |
Stock Splits
Satellos Bioscience Inc.'s most recent stock split took place on January 30, 2026 with a 12:1 split ratio.
| Last Split Date | 1/30/2026 |
| Split Ratio | 12:1 |
Scores
Satellos Bioscience Inc. posts an Altman Z-Score of 20.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 20.64 |